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O-GlcNAcylation and the Metabolic 
shift in High-Proliferating cells: All 
the evidence suggests that sugars 
Dictate the Flux of Lipid Biogenesis 
in tumor Processes
Steffi F. Baldini and Tony Lefebvre*
University Lille, CNRS, UMR 8576, UGSF, Unité de Glycobiologie Structurale et Fonctionnelle, Lille, France
Cancer cells are characterized by their high capability to proliferate. This imposes 
an accelerated biosynthesis of membrane compounds to respond to the need for 
increasing the membrane surface of dividing cells and remodeling the structure of lipid 
microdomains. Recently, attention has been paid to the upregulation of O-GlcNAcylation 
processes observed in cancer cells. Although O-GlcNAcylation of lipogenic transcrip-
tional regulators is described in the literature (e.g., FXR, LXR, ChREBP), little is known 
about the regulation of the enzymes that drive lipogenesis: acetyl co-enzyme A carboxy-
lase and fatty acid synthase (FAS). The expression and catalytic activity of both FAS and 
O-GlcNAc transferase (OGT) are high in cancer cells but the reciprocal regulation of the 
two enzymes remains unexplored. In this perspective, we collected data linking FAS and 
OGT and, in so doing, pave the way for the exploration of the intricate functions of these 
two actors that play a central role in tumor growth.
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Fatty acids are not only a form of energy storage but are also major components of biological 
membranes that delimit cells and organelles. They also govern essential biological functions, which 
include signal transduction and cell signaling, by forming exchange platforms between extracellular 
and intracellular media, in which signaling proteins are anchored.
Fatty acids are provided either by diet or de novo synthesis from carbohydrates. This metabolic 
pathway, called lipogenesis, is governed by fatty acid synthase (FAS), an enzyme upregulated in 
cancer. The activity and expression of O-GlcNAc transferase (OGT) that catalyzes O-GlcNAcylation 
processes in a nutrient-dependent manner are also increased in tumor cells. Consequently, increases 
in fatty acids production and O-GlcNAcylation levels are observed in cancer. Both enzymes indi-
rectly use the same substrate, glucose, whose flux is potentiated in cancer cells. Moreover, FAS and 
a fraction of OGT are in close proximity at the plasma membrane. Therefore, a cross-regulation 
between FAS and OGT is likely to exist.
FAs AND OGt Are UPreGULAteD iN cANcer
In physiological conditions, circulating lipids supply most human tissues with fatty acids. In strik-
ing contrast, high-proliferating cancer cells use increased fatty acid synthesis to support their rate 
of division (1, 2). De novo lipogenesis converts glucose to fatty acids. First, glucose is metabolized 
FiGUre 1 | regulation of fatty acid synthase by O-GlcNAcylation, Terra incognita. FAS expression and O-GlcNAcylation levels are dependent on glucose 
concentrations. Following its entry into the cell, glucose can engage in different metabolic pathways depending on the cell type and the physiological context 
(glycolysis, glycogenogenesis, pentose phosphate pathway, etc.). HBP converts a fraction of glucose into UDP-GlcNAc, the donor for O-GlcNAcylation processes. 
Either for storing energy or for the biosynthesis of membranes of proliferating cells, a large pool of glucose can be used for making fatty acids of which FAS (fatty 
acid synthase) is a key enzyme. FAS forms a head-to-head X-shaped homodimer. Each 273 kDa-subunit of FAS is an assembly line of fatty acids endowed with 
seven different catalytic activities. First, the acetyl moiety provided by acetyl-CoA is transferred to the thiol group of the phosphopantetheine part of ACP (acyl carrier 
protein) that transports the growing fatty acid chain from one catalytic domain to another via the acetyltransferase (AT); it is presented to ketoacylsynthase (KS). 
Then, malonyl transferase (MT) transfers the malonyl moiety from malonyl-CoA to ACP, and KS condensates the malonyl and acetyl groups. The β-ketoacyl-ACP is 
modified by a succession of three reactions. Ketoreductase (KR) reduces β-ketoacyl to a β-hydroxyl intermediate; a dehydratase (DH) produces a β-enoyl-ACP, 
which is reduced by the enoyl reductase (ER) to supply a saturated acyl chain elongated by a two-carbon unit. This product is the substrate for the condensation 
with another malonyl-ACP in the next sequence of elongation. This cycle is repeated until a C16:0 is reached; the end product is finally released by the thioesterase 
activity (TE). Since there is a close Relationship between intracellular glucose, O-GlcNAcylation levels, and activation of glucido-lipidic metabolism, a link between 
OGT, O-GlcNAcylation level, expression, and activity of FAS should exist. In cancer cells, the increased expression of OGT might lead to an increase in FAS 
expression. FAS participates in the production of phosphoinositides found in lipid rafts; these lipid microdomains can recruit OGT in the close proximity of FAS 
increasing its activity and, thus, to an expansion of membrane surface necessary for cell proliferation.
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into pyruvate, the end product of glycolysis that in turn enters 
the mitochondria to be activated into acetyl-CoA (Figure  1). 
The Lardy cycle enables the release of acetyl-CoA in the cytosol 
where lipogenesis takes place. Acetyl-CoA is carboxylated 
by Acetyl-CoA Carboxylase (ACC) to form malonyl-CoA. 
Malonyl-CoA and acetyl-CoA are the substrates of FAS that 
forms the final product, palmitoyl-CoA (C16:0). Longer fatty 
acids (e.g., stearic acid, C18:0) are produced by elongases, and 
mono-insaturated palmitoleoyl-CoA (C16:1) and oleyl-CoA 
(C18:1) are produced by SCD-1 (Stearoyl-CoA desaturase 
1). ACC, FAS, and SCD-1 are the main enzymes that control 
lipogenesis (3–6).
Overexpression of FAS and enhancement of its activity 
represent one of the most frequent phenotypic alterations in 
tumor cells. FAS is overexpressed in several human carcino-
mas, such as breast (7), colon (8), esophageal (9), lung (10), 
melanoma (11), ovarian (12), pancreatic (13), prostate (14), 
and stomach (15) cancers. Injection of transgenic mice with 
prostate cancer cells overexpressing FAS leads to the develop-
ment of adenocarcinomas (16). On the contrary, the FAS 
inhibitor C75 drives apoptosis in human breast cancer cells (17, 
18). ACC is overexpressed in breast (19) and prostate cancers, 
and blockade of its expression induces growth inhibition of 
cancer cells (20). Additionally, an elevated SCD-1 expression 
results in cancer cell proliferation (21), whereas its decrease 
results in cell death (22).
Long-chain saturated fatty acids (LCSFA) are crucial for 
the building of lipid microdomains, or detergent-resistant 
membranes (DRMs). DRMs ensure the correct localization and 
activation of receptors that potentiate signaling pathway activa-
tion and, consequently, cell proliferation (1, 23). Moreover, the 
switch from polyunsaturated to saturated and mono-unsaturated 
fatty acids in the composition of their membranes endows cancer 
cells with a better resistance to lipid peroxidation and, therefore, 
to oxidative stress-induced cell death (24). Furthermore, the 
increase in membrane density and compaction limits drug entry, 
rendering tumor cells more resistant to therapy. Finally, fatty 
acids contribute to the production of secondary messengers, such 
as phosphatidylinositol-3,4,5-triphosphate (PIP3) and lysophos-
phatic acid (LPA), that activate, respectively, the mitogenic 
PI3-kinase/Akt pathway (25) and G protein coupled-receptors 
that promote cancer aggressiveness (26). Consequently, fatty 
acids confer survival, resistance to damage, and aggressiveness 
on cancer cells.
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Glucose consumption is vital for most living cells. In normal 
cells, glucose is catabolized to pyruvate through glycolysis 
(Figure 1). Then, pyruvate is converted to acetyl-CoA and oxi-
dized to carbon dioxide via the mitochondrial tricarboxylic 
acid (TCA) cycle for maximal energy production. Cancer cells 
exhibit a deregulated glucido-lipidic metabolism. Indeed, cancer 
cells import glucose at a higher rate than non-cancer cells and 
prefer to use glycolytic metabolism instead of oxidative phos-
phorylation even in the presence of oxygen. This choice enables 
most cancer cells to produce the elementary building-bricks they 
need to divide (amino-acids, nucleotides, fatty acids,… etc.). 
Consequently, glycolytic enzymes and glucose transporters are 
upregulated. This adaptive metabolic shift is called the “Warburg 
effect” (27).
Interestingly, 2–3% of glucose coming into the cell enters the 
HBP (hexosamine biosynthesis pathway) whose end product 
is UDP-GlcNAc. This nucleotide sugar is at the crossroads of 
many metabolic pathways: carbohydrates, glutamine, glucogenic 
and ketogenic amino-acids, nucleotides, and fatty acids. UDP-
GlcNAc is a substrate for almost all glycosylations, including 
O-GlcNAcylation (28, 29). O-GlcNAcylation is a highly dynamic 
PTM (posttranslational modification) controlled by two antago-
nistic enzymes: OGT transfers the GlcNAc group onto serine or 
threonine residues of nucleocytoplasmic (30) and mitochondrial 
(31) proteins, and O-GlcNAcase removes the sugar (32). Thus, 
O-GlcNAcylation regulates diverse biological processes in 
a nutrient-dependent manner. O-GlcNAcylation occurs on 
several hundred proteins, which are mainly phosphoproteins. 
Accordingly, O-GlcNAcylation and phosphorylation can 
antagonize each other, at the same site or at an adjacent one, or 
act in concert (33). Moreover, a deregulation of O-GlcNAcylation 
homeostasis leads to disorders, such as diabetes, cancer, neuro-
logical, or cardiovascular diseases (34). Since, cancer cells accel-
erate the uptake of glucose and glutamine, an increase in HBP 
flux and aberrant O-GlcNAcylation contents result. Elevation of 
O-GlcNAcylation levels is observed in several kinds of cancers, 
such as breast (35), lung (36), colorectal (37), liver (38), bladder 
(39), prostate (40), chronic lymphocytic leukemia (CCL) (41), and 
pancreatic (42) cancers, suggesting that hyper-O-GlcNAcylation 
precedes or accompanies tumor emergence and contributes to 
cell transformation. The O-GlcNAcylation elevation observed in 
cancer cells seems also to be caused by an increased OGT expres-
sion. Indeed, OGT is overexpressed in breast (35), prostate (40), 
colorectal (36, 43), and pancreatic cancer cells (42). Interestingly, 
the inhibition of OGT in breast cancer cells induces a reduction 
in cell proliferation, invasion, and migration, and a decrease in 
tumor growth (35, 44).
An upregulation of FAS and OGT, and consequently an 
elevated production of fatty acids combined with an increase in 
the O-GlcNAcylation level are observed in cancer. Both enzymes 
indirectly use the same substrate, glucose, and glutamine for 
OGT, the fluxes of which are accelerated in tumor cells (Figure 1). 
Moreover, FAS and a fraction of OGT are in close proximity at 
the plasma membrane. Therefore, we postulate that FAS favors 
the interaction of OGT with phosphoinositides via its PPO (PIP-
binding activity of OGT) domain and in turn OGT controls the 
expression and catalytic activity of FAS (Figure 1).
FUtUre DirectiONs
Glucose and insulin control the expression of FAS at the 
transcriptional level through the activity of four transcription 
factors: carbohydrate-responsive element-binding protein 
(ChREBP), liver X receptors (LXR), farnesoid X receptor (FXR), 
and sterol regulatory element-binding proteins (SREBP) (Figure 2, 
pathway 1). ChREBP is a transcription factor that  mediates 
glucose-induced gene expression, including those encoding 
the glycolytic enzyme L-pyruvate kinase (L-PK) and lipogenic 
enzymes, ACC, and FAS. Glucose activates ChREBP by control-
ling its nuclear import (45) and ChREBP plays an essential role in 
the regulation of energy metabolism. A deregulation of ChREBP 
activity or its expression is involved in metabolic diseases, such 
as hepatic steatosis (46). Moreover, a deregulation of ChREBP is 
described in colorectal cancer and hepatoblastoma. A suppression 
of ChREBP decreases aerobic glycolysis, de novo lipogenesis, and 
nucleotide biosynthesis (47). Since cancer cells overconsume 
glucose and increase the biosynthesis of fatty acids, the role of 
ChREBP as a key-mediator of glucose-induced lipogenic gene 
expression was explored in the context of tumor metabolism (48). 
In response to high glucose influx as observed in cancer cells, 
ChREBP is activated in two distinct ways. First, controversial 
studies reported that Xu5P and Glc6P, two glucose metabolites, 
promote the translocation of ChREBP into the nucleus and binding 
to response elements (49). Second, ChREBP physically interacts 
with OGT and is O-GlcNAcylated in liver cells (50). Inhibition 
of OGA, or overexpression of OGT, significantly increases the 
transcriptional activity of ChREBP in response to high glucose. 
OGA-treated db/db mice display a decrease in FAS expression 
and escape hepatic steatosis in correlation with a downregulation 
of the O-GlcNAcylation of ChREBP (50, 51). LXRs belong to the 
superfamily of nuclear hormone receptors activated by the natural 
ligands oxysterols (52). LXRs bind to LXR-responsive elements 
(LXRE) in cooperation with RXR (9-cis retinoic acid receptor) 
and activate FAS transcription. LXRs either directly bind to the 
promoter of FAS, or indirectly increases the expression of FAS by 
upregulating the transcription of ChREBPα, the short isoform 
ChREBPβ and SREBP1c (53, 54). LXRs are O-GlcNAc-modified 
(55, 56) and O-GlcNAcylation enhances their ability to regulate FAS 
 expression. Furthermore, O-GlcNAcylated LXRs have increased 
capability to activate the transcription of SREBP1c and ChREBP, 
which reinforces the expression of FAS. Regarding SREBPs less is 
known about their potential regulation by O-GlcNAcylation. Of the 
three isoforms documented, SREBP1a, SREBP1c and SREBP2 (57), 
only SREBP1c is involved in the expression of FAS (58). No studies 
have focused on the regulation of SREBP by O-GlcNAcylation, 
while it is thought that GFAT-1, the rate-limiting enzyme of HBP, 
interferes with the activity of SREBP1 and FAS (59). Interestingly, 
an FXR response element is found in the promoter region of FAS. 
FXR is another member of the nuclear receptor superfamily and 
is activated by bile acids, chenodeoxycholic acid being the most 
potent. Unlike other transcription factors, FXR downregulates FAS 
expression (60). It was recently shown that FXR and OGT interact 
(61). FXR is O-GlcNAcylated and this modification enhances FXR 
transcriptional activity and stability. Interestingly, FXR interacts 
with ChREBP through its ATF-1 domain, which also bears the 
FiGUre 2 | Many putative pathways exist to regulate FAs by OGt and O-GlcNAcylation, and vice versa. Increased-O-GlcNAcylation and FAS 
overexpression are two features of cancer cells. In this perspective, we gathered data that suggest that a dialog between OGT and FAS potentiates cell proliferation. 
The different modes by which FAS and OGT might interact are the following: (1) indirectly, FAS mRNA level is regulated by O-GlcNAcylation. The transcription of FAS 
is coordinated by four transcription factors, ChREBP, SREBP1c, FXR, and LXR. SREBP1c and ChREBP are themselves regulated by LXR in an O-GlcNAcylation-
dependent manner. The activity of ChREBP, FXR, and LXR is directly linked to their O-GlcNAcylation status. (2) There are few descriptions of the modification of FAS 
by phosphorylation but a complex interplay between O-GlcNAcylation and phosphorylation cannot be discarded. (3) In cancer cells, both FAS and OGT are 
upregulated. It is also known that the enzymes are resident in lipid rafts, platforms of signal transduction and cell signaling. Thus, FAS and OGT might be interacting 
partners in lipid microdomains. FAS may contribute to the interaction of OGT with a specific subset of fatty acids of lipid microdomains, especially 
phosphoinositides, and, in turn, OGT may upregulate FAS activity. Consequently, receptor tyrosine kinases should cluster and increase the activation of signaling 
pathways and cell proliferation. (4) FAS homodimer assembly is F2,6BP dependent. F2,6BP also controls the oligomerization of PFK-1, the rate-limiting enzyme of 
glycolysis (63). O-GlcNAcylation of PFK-1 at S529 impinges on the binding site of F2,6BP and negatively regulates its activity. By contrast, we speculate whether 
O-GlcNAcylation favors FAS dimerization and activity. (5) The increased-flux of glucose uptake observed in cancer cells enhances the production of acetyl-CoA and 
malonyl-CoA, the substrates of FAS, and UDP-GlcNAc (in parallel with the accelerated-flux of glutamine in tumor cells), the donor of GlcNAc for the O-GlcNAcylation 
processes. It can be envisioned that one or several catalytic activities of FAS are directly under the control of OGT through their O-GlcNAcylation. Therefore, FAS 
might be controlled by glucose in two distinct ways: by enhancing the availability of substrates and by the posttranslational modification by O-GlcNAc moieties. (6) 
The O-GlcNAcylation of FAS may potentiate the interaction with the deubiquitinase USP2a and/or destabilize its interaction with the E3-ubiquitin ligase COP1, 
rendering the enzyme less sensitive to ubiquitin-dependent degradation.
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O-GlcNAcylation site (61, 62). However, the biological relevance 
of FXR O-GlcNAcylation in the context of its interaction with 
ChREBP remains to be elucidated. Transcriptional processes may 
account for a large part of the upregulation of FAS in cancer. What 
we do not know is whether, and if so, how, an elevation of the 
O-GlcNAcylation status of ChREBP, SREBP, and LXR, all driving 
FAS transcription, mediates the lipogenic enzyme overexpression 
in cancer cells, and, on the opposite, if O-GlcNAcylation of FXR 
reduces its expression. Further studies are necessary to highlight 
this intriguing problem.
O-GlcNAcylation and phosphorylation are two PTMs occur-
ring on serine and threonine residues of nucleocytoplasmic pro-
teins. They not only can compete at the same or at adjacent sites 
of the same protein in a reciprocal manner, but can also act syn-
ergistically: treatment of neuroblastoma cells with the wide range 
phosphatase inhibitor okadaic acid reduces O-GlcNAcylation 
(64), while inhibition of GSK3β increases O-GlcNAcylation 
of heat shock and cytoskeletal proteins but decreases the 
O-GlcNAcylation of other proteins such as transcription factors 
(65). These observations prove that the interplay between phos-
phorylation and O-GlcNAcylation is complex and should result 
from diverse complexes, including OGT, OGA, kinases, and 
phosphatases (66). Little is known about the regulation of FAS by 
PTMs. FAS is phosphorylated by AMP-activated protein kinase 
(AMPK) in 3T3-L1 cells and the use of AMPK activators reduces 
FAS activity without affecting its expression level (67). An upregu-
lation of FAS by occupation of the AMPK phosphorylation site by 
O-GlcNAc is hypothetical, but deserves to be explored (Figure 2, 
pathway 2). In addition, OGT is a substrate of AMPK (at T444) 
and reciprocally, AMPK is O-GlcNAcylated on at least two of 
its subunits (68). The potential occurrence of a ternary complex 
FAS–OGT–AMPK may explain how the lipogenic enzyme is reg-
ulated by phosphorylation and O-GlcNAcylation either directly, 
involving modification by AMPK-directed phosphorylation 
and/or O-GlcNAcylation, or indirectly, with phosphorylation by 
AMPK through a preliminary O-GlcNAcylation of the kinase or 
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O-GlcNAcylation by OGT following a preliminary modification 
of the glycosyltransferase by AMPK (pT444).
O-GlcNAc transferase and FAS might reciprocally regulate each 
other in lipid microdomains and O-GlcNAcylation might inter-
fere with FAS subcellular localization. It was demonstrated that 
FAS is tyrosine-phosphorylated when in a complex with HER-2 
(human epidermal growth factor receptor-2) in breast cancer 
cells (69). Phosphorylation of FAS by HER-2 leads to an increase 
in FAS catalytic activity. OGT is also tyrosine-phosphorylated 
and it was proposed that the insulin receptor is responsible for 
this modification (70). Moreover, OGT interacts with the plasma 
membrane via the PPO domain (71) and more particularly with 
DRMs in response to insulin (72). DRMs, also known as lipid 
microdomains or lipid rafts, are membrane domains enriched 
with cholesterol, sphingolipids, and gangliosides that concentrate 
modulators of signal transduction, trafficking, and cell signaling. 
Lipid rafts are fundamental for cell adhesion, migration, and 
proliferation in physiological conditions and in cancer (73). FAS 
controls the production of phospholipids found in DRMs of can-
cer cells (1) and a subset of FAS itself is resident in these rafts (74). 
Consequently, in response to insulin or to any other mitogenic sig-
nal, FAS might be activated by tyrosine-phosphorylation. In turn, 
raft-specific phospholipids and more precisely phosphoinositides 
might be produced, offering an interaction surface for OGT 
(Figure 2, pathway 3). FAS and OGT might physically interact: 
OGT may modify FAS and signaling components to upregulate 
their activities. This interaction could induce an increase in FAS 
activity in lipid microdomains and allow the formation of a larger 
cluster of signaling receptors and a more significant activation of 
signaling pathways, leading to an increase in cell proliferation, 
contributing to the development of cancer. It would be of interest 
to determine whether a synergistic effect between FAS and OGT 
exists in lipid rafts, accentuating their respective activities. This 
hypothesis is supported by reports showing that, in Drosophila 
(75), HepG2 cells (72), MCF7 cells (76), and recently in human 
gastric cancer cells (77), OGT activity is crucial for activating 
mitogen signaling pathways.
Another question remains open: does O-GlcNAcylation regu-
late FAS catalytic activity? FAS is only enzymatically active in the 
form of a dimer (78), the dissociation of the enzyme into mono-
mers rendering it inactive (79). The assembly of the two subunits 
is promoted by a high concentration of fructose-2,6-bisphosphate 
(F2,6BP), a metabolic cue. Therefore, since in cancer cells glucose 
uptake is increased, the rate of production of F2,6BP is enhanced, 
promoting FAS assembly and activity. A parallel can be drawn 
with Phosphofructokinase-1 (PFK-1) whose allosteric activity 
is positively regulated by F2,6BP. O-GlcNAcylation of PFK-1 
blocks the interaction with F2,6BP preventing the oligomeriza-
tion of the enzyme and the flux of glucose is rerouted to the 
pentose phosphate pathway (63). Conversely, a regulation of 
FAS activity by promoting its dimerization by O-GlcNAcylation 
could be envisioned (Figure  2, pathway 4). O-GlcNAcylation 
can impact the function of FAS by directly modifying residues 
crucial for one or several of its seven catalytic activities. In our 
hands, in silico studies of the 3D structure of FAS have indicated 
a potential O-GlcNAcylation site in close proximity to the ketoa-
cylsynthase (KS) active site (Figure 2, pathway 5). As discussed 
above, these studies must be pushed forward by identifying the 
O-GlcNAcylation sites through mass spectrometry.
Lastly, O-GlcNAcylation might regulate the fate of FAS. FAS 
is targeted for degradation by interacting with the E3-ubiquitin 
ligase p38-phosphorylated COP1 and the adapter protein Src-
homology 2 (SH2) domain-containing tyrosine phosphatase 
Shp2 (80). To escape the ubiquitination pathway, FAS interacts 
with the ubiquitin-specific protease-2a USP2a, a member of 
the DUB (deubiquitinating enzyme) family. By binding to FAS, 
USP2a increases the half-life of the enzyme in prostate cancer 
and, therefore, plays a prominent role in cancer progression (81). 
In addition, USP2a overexpression protects human prostate can-
cer from apoptosis (82). Altogether, these observations indicate 
that USP2a and FAS contribute to tumorigenesis. Like USP2a, 
OGT is also protective against protein degradation for a subset of 
proteins [for review, see Ref. (83)] among which β-catenin (43) 
and PGC-1α (84). O-GlcNAcylation of β-catenin at T41 prevents 
the phosphorylation of the D-box (43) and potentially the  sub-
sequent recruitment of the E3-ubiquitin ligase β-TrCp. The host 
cell factor C1 (HCF-1) recruits OGT to O-GlcNAcylate PGC-1α 
(84); the O-GlcNAcylation facilitates the recruitment of BAP1 to 
deubiquitinate PGC-1α, thereby stabilizing its expression level. 
Nevertheless, unlike β-catenin, the sequential events that decide 
the fate of FAS are poorly understood; it is not known, for exam-
ple, whether phosphorylation of FAS promotes its ubiquitination. 
Also, since FAS is not a short half-life protein, it is unlikely that 
a PEST sequence or a D-box regulates the proteasomal degrada-
tion of the protein. Accordingly, it might be proposed that OGT 
interacts with FAS either to promote the recruitment of USP2a 
or to prevent ubiquitination by COP1, both effects leading to 
increased-FAS half-life (Figure 2, pathway 6).
cONcLUsiON
Cancer cells are characterized by their high capacity for division. 
To supply their need for carbon elements, these cells increase the 
uptake of glucose and move from oxidative to glycolytic metabo-
lism. This metabolic shift leads to the overexpression of lipogenic 
enzymes, especially FAS. In addition, through the increased flux 
of HBP, cancer cells display higher levels of OGT and, therefore, 
of O-GlcNAcylation. Here, we have attempted to compile poten-
tial cross-regulations between FAS and OGT. We have identified 
pathways to explore that may highlight how the lipogenic enzyme 
could be finely tuned by O-GlcNAcylation.
First, upregulating glycolysis impacts the production of the 
allosteric activator F2,6BP. Checking whether this metabolic 
cue controls the homodimerization of FAS in an O-GlcNAc-
dependent manner should be of great interest considering its 
impact on the oligomerization of another pivotal metabolic 
enzyme, PFK-1. However, at this time, no information about 
the O-GlcNAc modification of FAS is available. This lack of 
data may result from the high molecular weight of the enzyme: 
analyzing the status of O-GlcNAcylation and, what is more, 
mapping sites of modification on a protein containing nearly 
3000 amino-acids is challenging. If such a modification of 
FAS occurs, the consequent regulation of one or more of its 
catalytic activities is conceivable.
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Regulation of FAS expression is tightly correlated to its mRNA 
level. Transcription of FAS is principally under the control of glu-
cose and insulin. Glucose activates ChREBP that in turn induces 
FAS transcription in cooperation with insulin-activated SREBP1c. 
LXR also increases FAS expression by binding to the promoters of 
FAS and SREBP1c. ChREBP, SREBP1c, and LXR are activated by 
O-GlcNAc modification, either directly or indirectly. By contrast, 
FXR downregulates FAS transcription and it is suggested that 
O-GlcNAcylation of this nuclear receptor potentiates ChREBP 
activity and, accordingly, FAS expression. Overall, it appears that 
O-GlcNAcylation drives the transcription of FAS positively.
The reciprocal interplay between phosphorylation and 
O-GlcNAcylation modulates the properties of numerous proteins. 
FAS activity is regulated at the posttranslational level by AMPK-
mediated phosphorylation; thus, the complex OGT–AMPK–FAS 
might exist but remains to be explored.
Fatty acid synthase and a small subset of OGT are resident 
in lipid microdomains. This common localization suggests that 
the two enzymes can be modified and, therefore, activated by 
tyrosine-phosphorylation. Also, a modification of FAS by OGT is 
not at all unlikely. Moreover, the production of lipid raft-specific 
fatty acids may contribute to the recruitment of OGT and speed 
up the sub-localization of the putative partners and the activation 
of mitogen signaling. Finally, as described for several proteins, 
O-GlcNAcylation of FAS could be protective against ubiquitin-
dependent degradation, by promoting interaction with USP2a or 
by preventing interaction with COP1.
To date, the regulation of FAS activity and fate by 
O-GlcNAcylation, and even more so its crosstalk with OGT, have 
been neglected. Nevertheless, we consider this field of investiga-
tion of crucial importance since such a regulatory mechanism 
might confer a proliferative advantage on cells and induce tumor 
emergence.
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